Ignite Creation Date:
2024-05-06 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 12:52 PM
Study NCT ID:
NCT03644966
Status:
COMPLETED
Last Update Posted:
2023-04-12
First Post:
2018-08-06
Brief Title:
Probiotics and Multi-Drug Resistant Urinary Tract Infection
Sponsor:
Ochsner Health System
Organization:
Ochsner Health System
Study Overview
Official Title:
Probiotic and Effects on Multi-Drug Resistant Urinary Tract Infection
Status:
COMPLETED
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This pilot study is a single-site randomized double blinded placebo-controlled in females with recurrent multi-drug resistant MDR urinary tract infectionsUTI Our study hypothesizes that a novel probiotic strain improves antibiotic sensitivity patterns in these former MDR UTIs
Detailed Description:
The aims of this study are 1 to evaluate the effects of six months of probiotic therapy in addition to standard of care in changing sensitivity patterns of MDR bacteria causing recurrent UTI 2 analyze the genetic composition of MDR bacterial isolates causing recurrent UTI before and after administration of probiotic vs placebo with standard of care antibiotics
Study subjects will be asked to take a either a probiotic supplement or placebo at a dose of 1 caplet per day for 24 weeks in addition to antibiotic regimen Subjects will be followed for 12 months The outcome measure is the percent of probiotic ingestors vs placebo ingestors who experience a change in antibiotic susceptibility over this time period The secondary outcome measure is the evaluation of genetic composition of bacteria recurring after probiotic vs placebo administration
Study subjects will be asked to take a either a probiotic supplement or placebo at a dose of 1 caplet per day for 24 weeks in addition to antibiotic regimen Subjects will be followed for 12 months The outcome measure is the percent of probiotic ingestors vs placebo ingestors who experience a change in antibiotic susceptibility over this time period The secondary outcome measure is the evaluation of genetic composition of bacteria recurring after probiotic vs placebo administration
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None